Amgen (AMGN) Revenue — Quarter Ended Mar 31, 2025
Revenue for the quarter decreased from the immediately preceding quarter but increased compared to the same quarter one year earlier. The sequential decline follows a period of growth, while the year-over-year gain reflects sustained expansion.
Key takeaway
Quarter ended Mar 31, 2025 · FY2025 Q1
Revenue for the quarter decreased from the immediately preceding quarter but increased compared to the same quarter one year earlier. The sequential decline follows a period of growth, while the year-over-year gain reflects sustained expansion.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$8.1B
Revenue reported for this quarter.
Quarter-over-quarter
-10.3%
Change from the immediately preceding quarter.
Year-over-year
+9.4%
Change from the comparable year-ago quarter.
Trailing four quarters
$34.1B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2024 | $8.4B | +20.1% |
| Sep 30, 2024 | $8.5B | +23.2% |
| Dec 31, 2024 | $9.1B | +10.9% |
| Mar 31, 2025 | $8.1B | +9.4% |
Revenue performance
The reported revenue moved lower quarter over quarter, reversing the prior period's increase. However, on an annual basis, revenue remained higher than the comparable quarter a year ago.
Quarterly comparison
Compared with the immediately preceding quarter, revenue declined, marking a downturn after a period of sequential gains. Versus the same quarter one year earlier, revenue rose, indicating underlying year-over-year strength.
What to watch
The sequential decline in revenue warrants monitoring for any further softening in the near term.